Obesity: Six trials to watch over the next 12 months

As more trials take place globally, not only will this help to provide a wider range of treatments for patients but will also assist the unmet need of lack of supply. Most of the current obesity treatments that target glucagon-like peptide 1 receptors (GLP-1’s) such as semaglutide, were originally used to treat type 2 diabetes. It is expected that due to recent advancements in obesity medication drugs targeting GLP-1’s as well as dual and triple-agonists will remain the primary mechanism of action (MOA).